AmpC-producing Enterobacteriaceae Research Articles

Molecular analysis of ESBL- and AmpC-producing Enterobacteriaceae in fecal samples from broiler and backyard chickens

ObjectiveTo analyse the molecular profile of antibiotic resistance in Enterobacteriaceae isolates from fecal samples of healthy broilers and backyard chickens in Tamil Nadu, India. MethodsA total of 115 and 57 bacterial strains were isolated from fecal samples of broiler and backyard chickens, respectively using conventional bacterial culture tests. Bacterial isolates were screened for antibiotic susceptibility by Kirby-Bauer’s disk diffusion method. Colistin susceptibility was tested using the broth microdilution method. Extended-spectrum β-lactamase (ESBL), AmpC β-lactamase and metallo-β-lactamase (MBL) producers were screened by combination disk method. The drug-resistant genes’ positivity was analysed by polymerase chain reaction (PCR) method. ResultsEscherichia coli was the predominant bacterium isolated from both broiler (53%) and backyard (64.9%) chickens. Bacterial isolates from broilers and backyard chickens showed 100% resistance to ampicillin, piperacillin, and piperacillin-tazobactam. Five bacterial isolates from broiler chickens were resistant to colistin. ESBL producers were 34.7% in broilers and 19.1% in backyard chickens. AmpC production was detected in 44.3% of the isolates from broilers and 26.2% of those from backyard chickens. Molecular analysis revealed that bacterial isolates from broiler chickens were positive for drug-resistant genes such as blaTEM (25%), blaSHV (5%), blaCTX-M (4%), blaAmpC (56%), integron (39%), sul1 (30%), and sul2 (23%). Bacterial isolates from backyard chickens were positive for the blaTEM (22%), blaSHV (14%), blaAmpC (54.3%), and integron (20%) genes. None of the isolates from either broiler or backyard chickens harboured New Delhi metallo-β-lactamase (blaNDM) or colistin-resistant genes (mcr-1 to −3). ConclusionsBacterial isolates from broiler chickens harboured a higher number of drug resistance genes, especially blaTEM, blaCTX-M, sul1, sul2, and integron, than those from backyard chickens.

Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice

IntroductionThis single-center study evaluated the efficacy and safety of tazobactam/ceftolozane (TAZ/CTLZ) in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice. MethodsThis study included 50 patients, including 35 with intraabdominal abscess or peritonitis, 5 with liver abscess, 4 with cholecystitis, and 6 with cholangitis with sepsis. Of the 50 patients, 29 received TAZ/CTLZ and metronidazole after a prior antibacterial therapy failure, including tazobactam/piperacillin, cefmetazole, and levofloxacin. Source control was performed in 36 patients. ResultsThe clinical response could be evaluated in 49 patients. The clinical cure rate at end-of-therapy was 91.8% (45 of 49 patients) and that at test-of-cure was 89.6% (43 of 48 patients). Of 5 patients in whom clinical response at test-of-cure was a failure, 1 developed infectious disease during chemoradiotherapy for recurrent cancer and 4 after liver resection or pancreatoduodenectomy. Three of the 4 patients were associated with pancreatic juice leakage. Isolated pathogens were eradicated or presumably eradicated in 27 of 31 (87.1%) patients in whom microbiological response at test-of-cure could be evaluated. The response rate for AmpC-producing Enterobacteriaceae was 87.5%. Nausea was observed in two patients. Aspartate and alanine aminotransferase activities were increased in 3 of the 50 (6.0%) patients. The activities improved after the antibiotic discontinuation. ConclusionsThis observational study demonstrated that TAZ/CTLZ in combination with metronidazole has a favorable effect without major drug-related adverse events for intraabdominal infection in the hepato-biliary-pancreatic field in clinical practice although the efficacy of TAZ/CTLZ may decrease in compromised patients.

Prevalence Escherichia coli, Klebsiella and Enterobacter Species and AmpC-producing Enterobacteriaceae in Clinical Specimens of Hospitals Affiliated to Babol University of Medical Sciences, Iran using Phenotypic and Molecular Methods

Prevalence Escherichia coli, Klebsiella and Enterobacter Species and AmpC-producing Enterobacteriaceae in Clinical Specimens of Hospitals Affiliated to Babol University of Medical Sciences, Iran using Phenotypic and Molecular Methods

Molecular Epidemiology of Extended-Spectrum Beta-Lactamase and AmpC Producing Enterobacteriaceae among Sepsis Patients in Ethiopia: A Prospective Multicenter Study.

Extended-spectrum beta-lactamases (ESBLs) and AmpC producing Enterobacteriaceae are public health threats. This study aims to characterize ESBL and AmpC producing Enterobacteriaceae isolated from sepsis patients. A multicenter study was conducted at four hospitals located in central (Tikur Anbessa and Yekatit 12), southern (Hawassa) and northern (Dessie) parts of Ethiopia. Blood culture was performed among 1416 sepsis patients. Enterobacteriaceae (n = 301) were confirmed using MALDI-TOF and subjected for whole genome sequencing using the Illumina (HiSeq 2500) system. The overall genotypic frequencies of ESBL and AmpC producing Enterobacteriaceae were 75.5% and 14%, respectively. The detection of ESBL producing Enterobacteriaceae at Hawassa, Yekatit 12, Tikur Anbessa and Dessie was 95%, 90%, 82% and 55.8%, respectively. The detection frequency of blaCTX-M, blaTEM and blaSHV genes was 73%, 63% and 33%, respectively. The most frequently detected ESBL gene was blaCTX-M-15 (70.4%). The common AmpC genes were blaACT (n = 22) and blaCMY (n = 13). Of Enterobacteriaceae that harbored AmpC (n = 42), 71% were ESBL co-producers. Both blaTEM-1B (61.5%) and blaSHV-187 (27.6%) were the most frequently detected variants of blaTEM and blaSHV, respectively. The molecular epidemiology of ESBL producing Enterobacteriaceae showed high frequencies and several variants of ESBL and AmpC genes. Good antimicrobial stewardship and standard bacteriological laboratory services are necessary for the effective treatment of ESBL producing Enterobacteriaceae.

Whole-Genome Sequencing of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli From Human Infections in Finland Revealed Isolates Belonging to Internationally Successful ST131-C1-M27 Subclade but Distinct From Non-human Sources.

Antimicrobial resistance (AMR) is a growing concern in public health, particularly for the clinically relevant extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacteriaceae. Studies describing ESBL-producing Escherichia coli clinical samples from Finland to the genomic level and investigation of possible zoonotic transmission routes are scarce. This study characterizes ESBL-producing E. coli from clinical samples in Finland using whole genome sequencing (WGS). Comparison is made between animal, food, and environmental sources in Finland to gain insight into potential zoonotic transmission routes and to recognize successful AMR genes, bacterial sequence types (STs), and plasmids. ESBL-producing E. coli isolates (n = 30) obtained from the Eastern Finland healthcare district between 2018 and 2020 underwent WGS and were compared to sequences from non-human and healthy human sources (n = 67) isolated in Finland between 2012 and 2018. A majority of the clinical isolates belonged to ST131 (n = 21; 70%), of which 19 represented O25:H4 and fimH30 allele, and 2 O16:H5 and fimH41 allele. Multidrug resistance was common, and the most common bla gene identified was blaCTX–M–27 (n = 14; 47%) followed by blaCTX–M–15 (n = 10; 33%). blaCTX–M–27 was identified in 13 out of 21 isolates representing ST131, with 12 isolates belonging to a recently discovered international E. coli ST131 C1-M27 subclade. Isolates were found to be genetically distinct from non-human sources with core genome multilocus sequence typing based analysis. Most isolates (n = 26; 87%) possessed multiple replicons, with IncF family plasmids appearing in 27 (90%) and IncI1 in 5 (17%) isolates. IncF[F1:A2:B20] replicon was identified in 11, and IncF[F-:A2:B20] in 4 isolates. The results indicate the ST131-C1-M27 clade gaining prevalence in Europe and provide further evidence of the concerning spread of this globally successful pathogenic clonal group. This study is the first to describe ESBL-producing E. coli in human infections with WGS in Finland and provides important information on global level of the spread of ESBL-producing E. coli belonging to the C1-M27 subclade. The results will help guide public health actions and guide future research.

The synergistic effect of turmeric aqueous extract and chitosan against multidrug-resistant bacteria

We aimed to investigate the antibacterial and antibiofilm effects of turmeric and chitosan against the planktonic and biofilm forms of multidrug-resistant (MDR) bacteria. A group of MDR bacteria, including clinical isolates of methicillin-resistant Staphylococcus aureus, carbapenem-resistant Pseudomonas, carbapenem-resistant Enterobacteriaceae and AmpC-producing Enterobacteriaceae, were collected by phenotypic and genotypic assays. The broth microdilution method was used to investigate the MIC of turmeric aqueous extract and chitosan. To investigate the synergistic effect of the combination of these natural compounds, we used the checkerboard assay. According to the results of this study, turmeric and chitosan showed inhibitory effects on MDR bacteria, especially on the planktonic form of methicillin-resistant S. aureus as a Gram-positive compared to tested Gram-negative bacteria (carbapenem-resistant Pseudomonas, carbapenem-resistant Enterobacteriaceae and AmpC-producing Enterobacteriaceae). The antibiofilm effect of turmeric and chitosan was found more often in carbapenem-resistant Pseudomonas isolates. There was no significant difference between the tested Gram-negative bacteria because most of the tested strains were inhibited in 512 and 1024 μg/mL concentrations of chitosan and turmeric aqueous extract. In this study, turmeric aqueous extract and chitosan exhibited significant antibacterial and antibiofilm properties. However, the effect of these compounds should be investigated using in vivo models for use in pharmaceutical and disinfectant formulations.

Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?

Sulbactam, a class A β-lactamase inhibitor, added to cefoperazone either at a fixed 8mg/L level of sulbactam or at a level of fixed cefoperazone: sulbactam ratio (2:1) would constitute a combination form of cefoperazone/sulbactam, which has better activities against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii than cefoperazone alone. Cefoperazone/sulbactam (1:1 or 1:2) has greater in-vitro activity against most multidrug-resistant organisms (ESBL- and AmpC-producing Enterobacteriaceae and carbapenem-resistant A. baumannii except for carbapenem-resistant P. aeruginosa) than a 2:1 ratio. However, increased sulbactam concentration may induce AmpC production. Besides, sulbactam concentration might not be readily achievable in serum if the susceptibility rates were defined by the breakpoints of higher sulbactam composites, such as ≤16/16 (1:1) or 16/32 (1:2) mg/L. Carbapenemases (KPC-, OXA-type enzymes and metallo-β-lactamases) can't be inhibited by sulbactam. Some in-vitro studies showed that increasing sulbactam composites of cefoperazone/sulbactam had no effect on carbapenem-resistant P. aeruginosa, suggesting the presence of carbapenemases or AmpC overproduction that could not be overcome by increasing sulbactam levels to recover cefoperazone activity. Sulbactam alone has good intrinsic activity against carbapenem-resistant Acinetobacter strains sometimes even in the presence of carbapenemase genes, suggesting unsteady levels of carbapenemases. In conclusion, appropriate composites of cefoperazone and β-lactamase inhibitor sulbactam may expand the clinical use if the pharmacokinetic optimization could be achieved in the human serum.

663. Improved Detection of ESBL and AmpC Beta-Lactamase Producing Isolates of Enterobacteriaceae in Pediatric Patients with Bloodstream Infections Using Combined Genotypic and Phenotypic Antimicrobial Susceptibility Testing

BackgroundInfections secondary to pathogens resistant to third-generation cephalosporins (3GC), such as extended-spectrum (ESBL) and AmpC β-lactamase (AmpC) producing Enterobacteriaceae, are increasing. Currently, there are no recommendations regarding identification of AmpC in Citrobacter, Enterobacter, Morganella and Serratia spp. (CEMS organisms). This study’s aim was to increase the detection of AmpC and ESBL producing Enterobacteriaceae in blood cultures from pediatric population by combining genotypic with phenotypic antimicrobial susceptibility testing (AST).MethodsAll first time Enterobacteriaceae isolates recovered from blood cultures of pediatric patients at CCHMC between January 2017 and December 2018 were evaluated. The Check-MDR CT103XL assay was used to determine the presence of AmpC and ESBL. AST was performed using the Vitek 2 platform. Phenotypic ESBL resistance was defined by resistant to either ceftriaxone of ceftazidime using CLSI breakpoints. Combined cefoxitin resistance with ceftriaxone or ceftazidime resistance was used to define phenotypic AmpC (EUCAST standards).ResultsThere were 170 isolates, from 147 patients, with 21 (12.4%) AmpC and 18 (10.6%) ESBL genes detected. Using AST, 11 (6.5%) and 26 (15.3%) isolates met AmpC and ESBL phenotypic criteria respectively. However, 14 of the isolates with AmpC genes detected and 2 of isolates with ESBL genes detected failed to meet phenotypic criteria. In addition, 4 (19%) of 21 AmpC isolates were susceptible to cefoxitin and 3GC while both E. coli and S. marcescens genotypic ESBL isolates were susceptible to 3GC.Number of AmpC- and ESBL- Producing Isolates Detected Using Phenotypic Method a,b, Genotypic Method and Combined Testing ConclusionWe identified 16 (9.4%) isolates with resistance genes detected but that failed to meet phenotypic criteria.Without molecular testing, patients with these isolates may have been treated with 3GC which could have resulted in treatment failure.The addition of genotypic testing to AST improved the identification of AmpC and ESBL organisms and provided clinically relevant data to guide treatment of resistant organisms. Combined testing is also beneficial for infection control and epidemiological purposes.Disclosures All Authors: No reported disclosures

Fluoroquinolone Versus Nonfluoroquinolone Treatment of Bloodstream Infections Caused by Chromosomally Mediated AmpC-Producing Enterobacteriaceae.

Objectives: Chromosomally mediated AmpC-producing Enterobacteriaceae (CAE) display high susceptibility to fluoroquinolones; minimal clinical data exist supporting comparative clinical outcomes. The objective of this study was to compare treatment outcomes between fluoroquinolone and nonfluoroquinolone definitive therapy of bloodstream infections caused by CAE. Methods: This retrospective cohort assessed adult patients with positive blood cultures for CAE that received inpatient treatment for ≥48 h. The primary outcome was difference in clinical failure between patients who received fluoroquinolone (FQ) versus non-FQ treatment. Secondary endpoints included microbiological cure, infection-related length of stay, 90-day readmission, and all-cause inpatient mortality. Results: 56 patients were included in the study (31 (55%) received a FQ as definitive therapy; 25 (45%) received non-FQ). All non-FQ patients received a beta-lactam (BL). Clinical failure occurred in 10 (18%) patients, with 4 (13%) in the FQ group and 6 (24%) in the BL group (p = 0.315). Microbiological cure occurred in 55 (98%) patients. Median infection-related length of stay was 10 (6–20) days, with a significantly longer stay occurring in the BL group (p = 0.002). There was no statistical difference in 90-day readmissions between groups (7% FQ vs. 17% BL; p = 0.387); one patient expired. Conclusion: These results suggest that fluoroquinolones do not adversely impact clinical outcomes in patients with CAE. When alternatives to beta-lactam therapy are needed, fluoroquinolones may provide an effective option.

Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia.

This article aims to give a state-of-the-art assessment of treatment options for bloodstream infection because of ceftriaxone-resistant Gram-negative bacilli, especially those caused by extended-spectrum beta-lactamase (ESBL) or AmpC-producing Enterobacteriaceae. In particular, this review assesses whether current data support 'carbapenem-sparing options' for treatment of these serious infections. The MERINO trial refuted earlier observational studies some of which showed equivalence in outcomes between beta-lactam/beta-lactamase inhibitor combinations and carbapenems for treatment of bloodstream infection because of ceftriaxone-resistant Escherichia coli or Klebsiella spp. Although numerous factors influence mortality following bloodstream infection, the variability in piperacillin/tazobactam MICs observed in the MERINO trial make this a less secure option than meropenem. However, the search for carbapenem-sparing options continues with four randomized controlled trials (RCTs) in progress and a number of other options in clinical development. Hard outcomes from RCTs are still needed before intravenous carbapenems can be displaced as the treatment of choice for ceftriaxone-resistant Gram-negative bacilli.

Petting Zoo Animals as an Emerging Reservoir of Extended-Spectrum β-Lactamase and AmpC-Producing Enterobacteriaceae.

Extended spectrum beta-lactamases and AmpC-producing Enterobacteriaceae (ESBL/AmpC-E) have become a great concern in both human and veterinary medicine. One setting in which this risk could be particularly prominent is petting zoos, in which humans, especially children, directly and indirectly interact with the animals. Yet, while the zoonotic transmission of various Enterobacteriaceae has been reported previously in petting zoos, reports on ESBL/AmpC-E shedding in this setting is currently lacking, despite the high potential risk. To fill this knowledge gap, we conducted a prospective cross-sectional study to explore the prevalence, molecular epidemiology, and risk for shedding of ESBL/AmpC-E in petting zoos. We performed a prospective cross-sectional study in eight petting zoos. Altogether, we collected 381 fecal and body-surface samples from 228 animals, broth-enriched them, and then plated them onto CHROMagar ESBL-plates for ESBL/AmpC-E isolation. Next, we identified the isolated species and tested their susceptibility to various antibiotics using the Vitek-2 system, determined bacterial relatedness by multilocus sequence typing (MLST), and identified ESBL/AmpC genes by using PCR and sequencing. Finally, we asked petting zoo owners and veterinarians to complete questionnaires, which we then analyzed to evaluate risk factors for ESBL/AmpC-E shedding. We found that ESBL/AmpC-E shedding is an important, currently oversighted risk in petting zoos, as the overall shedding rate was 12% (35 isolates, including 29% ESBL-producers, 34% AmpC-producers, and 37% ESBL and AmpC-producers). The isolated bacteria included Enterobacter cloacae (55%), Escherichia coli (31%), and Citrobacter freundii (14%), with diverse ESBL genes. MLST revealed diverse sequence types (STs), including the highly virulent Enterotoxigenic ST656 and the Uropathogenic ST127 E. coli strains, indicating complex epidemiology with inter-animal bacterial transmission. Shedding was associated with petting permission and antibiotic treatment in the petting zoo (OR = 7.34), which were identified as risk factors for ESBL/AmpC shedding. Our findings highlight petting zoos as a source for antibiotic-resistant ESBL/AmpC-producing bacteria, including highly virulent, disease-associated MDR E. coli strains. As this risk has not been previously described in detail, it calls for the implementation of infection control and active surveillance programs in petting zoos and raises the need for a comprehensive guideline to restrain this emerging concern.

Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae.

Chromosomal AmpC β-lactamase induction by several types of β-lactams has been reported, but not enough data are available on DHA-1 β-lactamase, a plasmid-mediated AmpC β-lactamase. Therefore, we evaluated the DHA-1 β-lactamase induction by various antibiotics including piperacillin/tazobactam (PIP/TZB) in this study. Six strains (Enterobacter cloacae 2 strains, Citrobacter freundii 1 strain, Serratia marcescens 2 strain, and Morganella morganii 1 strain) possessing chromosomal inducible AmpC β-lactamase were used as controls. Four strains (Escherichia coli 2 strains, Klebsiella pneumoniae 1 strain, and C. koseri 1 strain) possessing DHA-1 β-lactamase were used. The β-lactamase activities were determined by a spectrophotometer using nitrocefin. β-lactamase induction by PIP, PIP/TZB was not observed in any strains and β-lactamase induction by third- and fourth-generation cephems was not observed in most strains. The induction ratios of the chromosomal AmpC β-lactamase in the reference group by PIP/TZB were <1.51, and those of the DHA-1 β-lactamase were <1.36, except for K. pneumoniae Rkp2004 (2.22). The β-lactamase induction by first- and second-generation cephems, flomoxef, and carbapenem differed in each strain. Cefmetazole (CMZ) strongly induced β-lactamase. This study demonstrated that the induction of DHA-1 β-lactamase was similar to that of chromosomal AmpC using various Enterobacteriaceae, although the induction of β-lactamase in both groups by PIP/TZB was low. We also reported that the induction of PIP/TZB, a β-lactamase inhibitor combination antibiotic, against various AmpC-producing Enterobacteriaceae, including DHA-1 producers, was low.

Performance of differential time to positivity as a routine diagnostic test for catheter-related bloodstream infections: a single-centre experience

To assess the performance of differential time to positivity (DTP) for the diagnosis of catheter-related bloodstream infections (CRBSI). From all episodes of bloodstream infections (BSI) diagnosed during a 15-year period (2003-17) those in which a paired set of blood cultures drawn from a catheter and a peripheral vein were positive for the same microorganism and had a clinically and/or microbiologically defined source were selected. To assess diagnostic discrimination ability and accuracy of DTP for CRBSI, area under the receiver operating characteristic curves (AUC) and performance characteristics of a DTP ≥2h were computed. A total of 512 BSI were included, of which 302 (59%) were CRBSI. Discrimination ability of DTP was low for Staphylococcus aureus (AUC 0.656±0.06), coagulase-negative staphylococci (AUC 0.618±0.081), enterococci (AUC 0.554±0.117) and non-AmpC-producing Enterobacteriaceae (AUC 0.653±0.053); moderate for Pseudomonas aeruginosa (AUC 0.841±0.073), and high for AmpC-producing Enterobacteriaceae (AUC 0.944±0.039). For the entire sample, DTP had a low-to-moderate discrimination ability (AUC 0.698±0.024). A DTP ≥2h has a low sensitivity for coagulase-negative staphylococci (60%) and very low for S.aureus (34%), enterococci (40%) and non-AmpC-producing Enterobacteriaceae (42%). A DTP cut-off of 1h improved sensitivity (90%) for AmpC-producing Enterobacteriaceae. Differential time to positivity performs well for diagnosing CRBSI only when AmpC-producing Enterobacteriaceae and P.aeruginosa are involved. Performance is low for common Gram-positive organisms and non-AmpC-producing enteric bacilli; a negative test should not be used to rule out CRBSI due to these microorganisms. A DTP ≥1h may improve accuracy for AmpC-producing Enterobacteriaceae, particularly Enterobacter spp.

Epidemiology of Serious Bacterial Infections in Infants Less Than 90 Days of Age, Presenting to a Tertiary Care Emergency Department, 2010 to 2016.

Serious infections in infants require urgent treatment. Microbiology of bacterial isolates obtained from children younger than 90 days of was reviewed. Nine-hundred thirty-two infants were identified (mean age of 39 days). Seventy-four percent of organisms obtained were relevent. Common pathogens identified were Escherichia coli, Streptococcus agalactiae and Staphylococcus aureus. Emergence of S. aureus (18% methicillin resistant S. aureus (MRSA)) and ampC producing enterobacteriaceae requires prompt attention.

Prevalence and characterization of β-lactamase-producing Enterobacteriaceae in healthy human carriers.

Presence of extended-spectrum β-lactamase (ESBL-E), AmpC-producing and carbapenemase-producing (CPE) Enterobacteriaceae has been observed not only in the clinical environment, but also in the out-of-hospital environment. The objective of this study was to isolate and characterize strains of ESBL, AmpC, and CPE present in feces of healthy carriers in Navarra (n = 125). Despite the fact that no CPE strains were isolated, 16% and 11.2% of the studied population were ESBL-E and AmpC carriers, respectively. No significant differences were found by gender or age; young people (5-18years old) showed the highest ESBL-E prevalence (31.8%). The isolates corresponded to E. coli (57.1%), Enterobacter spp. (28.6%), and Citrobacter freundii (14.3%), and all strains showed multidrug-resistant profiles. High resistance against cephalosporins, penicillins, and monobactams, and sensitivity to carbapenems, quinolones, and aminoglycosides were observed. With respect to ESBL producers, 52.4% were CTX-M-type (19.0% CTX-M-14, 9.5% CTX-M-1, and 28.6% CTX-M-15) and 47.6% were TEM-type (38.1% TEM-171). These results confirm the extensive dissemination of these resistances among a healthy population and pose the need to implement control measures and strategies according to the One Health approach in order to prevent the increase of severe and untreatable infections in a not far future.

Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis.

The optimal treatment for potential AmpC-producing Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, remains unknown. An updated systematic review and meta-analysis of studies comparing beta-lactam/beta-lactamase inhibitors with carbapenems in the treatment of bloodstream infections with these pathogens found no significant difference in 30-day mortality (OR, 1.13; 95% CI, 0.58 – 2.20).

Gene Families of AmpC-producing Enterobacteriaceae Present in the Intensive Care Unit of Cipto Mangunkusumo Hospital Jakarta

BACKGROUND: Antibiotic resistance has become a worldwide problem. Among Asia countries, Indonesia has high prevalence of multi-drug resistant organisms mainly due to Gram-negative bacilli Enterobacteriaceae. This study aimed to find out whether gene family of AmpC and AmpC/ESBL-producing Enterobacteriaceae were present in the Intensive Care Unit (ICU) of Cipto Mangunkusumo Hospital, Jakarta, Indonesia.METHODS: Specimens were obtained from several body sites of adult patients with infection hospitalised in ICU of Cipto Mangunkusumo Hospital. VITEK®2 was used to identify the microorganisms. Antibiotic susceptibility tests were conducted using VITEK®2 and disc diffusion technique according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Double disc synergy (DDS) test method was employed to detect AmpC activity. Gene families of ampC were identified using multiplex polymerase chain reaction (PCR).RESULTS: Forty five isolates were identified as putative AmpC, extended-Spectrum β-lactamases (ESBL) and AmpC/ESBL-producing Enterobacteriaceae. Klebsiella pneumoniae (n=32) were predominant, followed by Escherichia coli (n=6), Enterobacter cloacae (n=5) and Enterobacter aerogenes (n=2). AmpC activity was detected in 9 isolates, in which 4 isolates were AmpC producing and 5 isolates were AmpC/ESBL. In vitro, AmpC-producing Enterobacteriaceae showed good susceptibility to many antibiotic tested, while those of AmpC/ESBL-producing only to Amikacin. The gene families of ampC were DHA, EBC and CIT identified from 6 isolates.CONCLUSION: DHA, EBC and CIT gene families were identified from AmpC and AmpC/ESBL-producing Enterobacteriaceae in the ICU of Cipto Mangunkusumo Hospital. While the AmpC-producing was still susceptible to almost all antibiotics tested, the AmpC/ESBL-producing showed resistant except for Amikacin.KEYWORDS: Enterobacteriaceae, β-lactamases, AmpC, ESBL

Mortality impact of empirical antimicrobial therapy inESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.

Treatment of ESBL- and AmpC-producing Enterobacteriaceae bacteremia is often complicated by lack of appropriate antibiotics. We aimed to determine the predictors of mortality and impact of empirical antibiotics. A retrospective observational study was performed on consecutive adult cases of ESBL and AmpC bacteremia at the Alfred Hospital from 2014 through April 2018. Among 110 patients with ESBL (88.2%) and AmpC (14.5%) bacteremia episodes, 96.4% had comorbidities such as hematological malignancy (30%). Approximately 45% were on immunosuppressive drugs, while 69% had recent antibiotic exposure. Over 84% of bacteremias were hospital acquired or healthcare associated. Urinary tract was the main source of infection (40%) with E. coli being the commonest organism (66.4%). The isolates were least resistant to gentamicin (21.8%), which was often appropriately used in empirical therapy. About 34% of patients presented with severe sepsis or shock. The 30-day mortality rate was 20% with no correlation with inappropriate empirical antibiotics (52%). There was no significant mortality difference between carbapenem use in empirical and definitive therapy. Respiratory source [OR 11.77, 95% CI 1.30-106.85; p=0.03], severe sepsis or shock [OR 5.17, 95% CI 1.37-19.55; p=0.02] and inappropriate definitive therapy [OR 27.93, 95%CI 3.69-211.35; p=0.001] were independent predictors for mortality. The choice and appropriateness of empirical therapy were not associated with mortality in ESBL and AmpC bacteremia. Prudent use of carbapenem is reasonable with gentamicin as alternative. Emphasis should be on prompt resuscitation in severe sepsis and early detection of ESBL and AmpC to facilitate appropriate switch to definitive therapy.

Contamination of chicken meat with extended-spectrum beta-lactamase producing- Klebsiella pneumoniae and Escherichia coli during scalding and defeathering of broiler carcasses

Extended-spectrum beta-lactamase- (ESBL-) producing Klebsiella (K.) pneumoniae and Escherichia (E.) coli are of critical importance in human and veterinary medicine. Animal food products, especially broiler chickens, are discussed as a possible source for the exposure of humans with antibiotic resistant bacteria. Although the occurrence and vertical transmission of ESBL-/AmpC-producing Enterobacteriaceae in the broiler production has been reported before, detailed investigations concerning the dissemination along the slaughter processing line are missing.In this study, we investigated cross-contamination with ESBL-producing Enterobacteriaceae during the processing of two different broiler flocks in one slaughterhouse. The ESBL-status during the fattening period of the flocks was determined and environmental samples from the slaughterhouse were taken before processing of the respective flocks. These isolates were compared to those found in samples from the carcasses after processing using whole genome sequencing. Phylogenetic analyses of seven ESBL-producing K. pneumoniae and 14 E. coli revealed close relationships between isolates from scalding water and the defeathering machine, respectively, which were collected before the processing of the broiler flocks, to those isolates found in samples from skin and filet of the respective flock carcasses. In conclusion, using high resolution molecular data we found evidence for the cross-contamination of carcasses with ESBL-producing Enterobacteriaceae during scalding and defeathering in the slaughterhouse.

Phenotypic Detection of Extended Spectrum β-Lactamase and AmpC producing Enterobacteriaceae Isolated in A General Hospital

Objective: The antibiotic resistance of Enterobacteriaceae is a worldwide preoccupation, and misuse&#x0D; antibiotics of beta-lactam group allowed the development of bacteria producing&#x0D; extended spectrum beta-lactamase and cephalosporinase AmpC enzymes type&#x0D; resistance. The aim of this study was to determine the frequency of these&#x0D; enzymes among strains isolated at the General Hospital in Douala, Cameroon.&#x0D; &#x0D; Methods: We&#x0D; conducted a cross-sectional study. For phenotypic detection of resistance&#x0D; enzymes, MASTDISCS™ test impregnated third and fourth generation&#x0D; cephalosporin’s was used by diffusion on Mueller Hinton agar. Measuring the&#x0D; inhibition areas and comparing the inhibition diameters determined the nature&#x0D; of the resistance mechanism.&#x0D; &#x0D; Results: This&#x0D; study included 195 strains of Enterobacteriaceae.&#x0D; The most frequent species were Escherichia&#x0D; coli and Klebsiella pneumoniae,&#x0D; with a frequency of 49.2% and 31.3% respectively. After determination of&#x0D; resistance phenotypes, 101 (51.8%) isolates were found to be producing&#x0D; resistance enzymes. The frequency of ESBL-producing Enterobacteriaceae was 19.5%; AmpC producing was 14.3% and both&#x0D; enzymes (AmpC + ESBL) 17.9%. E. coli&#x0D; and K. pneumoniae resistance rates&#x0D; were 90% and 83.7% for Cotrimoxazole, 82.5% and 78.3% for ciprofloxacin, 20%&#x0D; and 13.5% for Amikacin, respectively. Imipenem, Amikacin and Fosfomycin were&#x0D; the most active molecules with 4.9%, 19.8% and 33.6%, out of 101 resistant&#x0D; strains, respectively.&#x0D; &#x0D; Conclusion: This study showed a high frequency of resistance&#x0D; enzyme producing strains. This situation leads to resistance to antibiotics&#x0D; most commonly used. This finding justifies a change in prescription habits for&#x0D; protection of molecules that are still active. J Microbiol Infect Dis 2018; 8(3):113-119